JP2020527559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527559A5 JP2020527559A5 JP2020501505A JP2020501505A JP2020527559A5 JP 2020527559 A5 JP2020527559 A5 JP 2020527559A5 JP 2020501505 A JP2020501505 A JP 2020501505A JP 2020501505 A JP2020501505 A JP 2020501505A JP 2020527559 A5 JP2020527559 A5 JP 2020527559A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023062212A JP2023106366A (ja) | 2017-07-12 | 2023-04-06 | タウタンパク質分解の化合物 |
| JP2024209477A JP2025060612A (ja) | 2017-07-12 | 2024-12-02 | タウタンパク質分解の化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531773P | 2017-07-12 | 2017-07-12 | |
| US62/531,773 | 2017-07-12 | ||
| PCT/US2018/041787 WO2019014429A1 (en) | 2017-07-12 | 2018-07-12 | COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023062212A Division JP2023106366A (ja) | 2017-07-12 | 2023-04-06 | タウタンパク質分解の化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527559A JP2020527559A (ja) | 2020-09-10 |
| JP2020527559A5 true JP2020527559A5 (https=) | 2021-08-19 |
| JP7260521B2 JP7260521B2 (ja) | 2023-04-18 |
Family
ID=65001509
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501505A Active JP7260521B2 (ja) | 2017-07-12 | 2018-07-12 | タウタンパク質分解の化合物 |
| JP2023062212A Withdrawn JP2023106366A (ja) | 2017-07-12 | 2023-04-06 | タウタンパク質分解の化合物 |
| JP2024209477A Pending JP2025060612A (ja) | 2017-07-12 | 2024-12-02 | タウタンパク質分解の化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023062212A Withdrawn JP2023106366A (ja) | 2017-07-12 | 2023-04-06 | タウタンパク質分解の化合物 |
| JP2024209477A Pending JP2025060612A (ja) | 2017-07-12 | 2024-12-02 | タウタンパク質分解の化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210154184A1 (https=) |
| EP (2) | EP3652329B1 (https=) |
| JP (3) | JP7260521B2 (https=) |
| AU (1) | AU2018300982B2 (https=) |
| CA (1) | CA3069181A1 (https=) |
| ES (1) | ES2965049T3 (https=) |
| WO (1) | WO2019014429A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2767532B1 (en) | 2012-12-21 | 2016-07-13 | National Institutes for Quantum and Radiological Science and Technology | Novel compound for imaging tau protein accumulated in the brain |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| IL290809B2 (en) * | 2016-11-01 | 2024-01-01 | Arvinas Operations Inc | Tau-protein targeting protacs and associated methods of use |
| BR112019017021A2 (pt) | 2017-02-17 | 2020-04-14 | Denali Therapeutics Inc | anticorpos anti-tau e métodos de uso dos mesmos |
| EP3652329B1 (en) * | 2017-07-12 | 2023-10-04 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
| LT3728207T (lt) | 2017-12-21 | 2023-05-25 | Ribon Therapeutics Inc. | Chinazolinonai kaip parp14 inhibitoriai |
| EP3774804A1 (en) | 2018-03-26 | 2021-02-17 | Novartis AG | N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives |
| CA3095912A1 (en) * | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CN118344338A (zh) | 2018-04-23 | 2024-07-16 | 细胞基因公司 | 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途 |
| JP7293343B2 (ja) | 2018-05-09 | 2023-06-19 | アプリノイア セラピューティクス リミテッド | ヘテロアリール化合物及びその使用 |
| WO2020027225A1 (ja) | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | 複素環化合物 |
| EP3841100A1 (en) | 2018-08-20 | 2021-06-30 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| JP7619952B2 (ja) * | 2019-02-25 | 2025-01-22 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | 変異型ハンチンチンタンパク質を標的とするための化合物及びその使用 |
| CN120172958A (zh) | 2019-04-12 | 2025-06-20 | C4医药公司 | Ikaros和aiolos的三环降解物 |
| CN120398840A (zh) * | 2019-06-19 | 2025-08-01 | 里邦医疗公司 | 用于治疗的parp14的靶向蛋白质降解 |
| CN119954801A (zh) | 2019-07-17 | 2025-05-09 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
| JP7785663B2 (ja) * | 2019-09-16 | 2025-12-15 | ノバルティス アーゲー | 二機能性分解誘導薬及びそれらの使用方法 |
| CA3161455A1 (en) * | 2019-11-13 | 2021-05-20 | Aprinoia Therapeutics Limited | Compounds for degrading tau protein aggregates and uses thereof |
| CN110878095B (zh) * | 2019-12-02 | 2023-01-24 | 中山大学 | 一种姜黄素双功能分子及其制备方法和应用 |
| JP2023518202A (ja) * | 2020-03-18 | 2023-04-28 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｐｅｔトレーサーｐｂｂ３に基づく異常タウの標的化ディグレーダー |
| EP4138921A1 (en) * | 2020-04-23 | 2023-03-01 | University Of Iowa Research Foundation | Gper proteolytic targeting chimeras |
| CN116234562A (zh) * | 2020-05-15 | 2023-06-06 | 非营利性组织佛兰芒综合大学生物技术研究所 | 用于治疗病理性聚集的手段和方法 |
| EP4157833A1 (en) * | 2020-05-28 | 2023-04-05 | Bristol-Myers Squibb Company | Galectin-3 inhibitors |
| JP2023530937A (ja) * | 2020-06-17 | 2023-07-20 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｅ３－リガーゼ系の共動員を介した標的化された異常なα－シヌクレイン種ならびに誘導されたユビキチン化およびプロテアソームクリアランス |
| WO2022201063A1 (en) * | 2021-03-23 | 2022-09-29 | Covabind Joint Research Private Limited | Nanoparticle composition for targeted protein degradation |
| JP2024517340A (ja) | 2021-05-14 | 2024-04-19 | アプリノイア セラピューティクス リミテッド | アルファ－シヌクレイン凝集物を分解する化合物及びその使用 |
| WO2022261627A1 (en) * | 2021-06-07 | 2022-12-15 | The General Hospital Corporation | Inhibitors of ttbk1 |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| WO2023036936A1 (en) * | 2021-09-09 | 2023-03-16 | Booster Therapeutics Gmbh | Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods) |
| EP4147723A1 (en) | 2021-09-09 | 2023-03-15 | Booster Therapeutics GmbH | Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods) |
| EP4602166A2 (en) * | 2022-10-11 | 2025-08-20 | The General Hospital Corporation | Engineered bifunctional receptors and uses thereof |
| WO2024182633A2 (en) * | 2023-03-01 | 2024-09-06 | The Regents Of The University Of California | Targeted dephosphorylation of tau |
| CN116344058B (zh) * | 2023-05-29 | 2023-08-18 | 之江实验室 | 一种基于图信号的阿尔兹海默风险标注方法及装置 |
| WO2025117551A1 (en) * | 2023-11-27 | 2025-06-05 | Amydis, Inc. | Amino acid derivatives for detecting neurological disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8932557B2 (en) * | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
| WO2013020125A1 (en) | 2011-08-04 | 2013-02-07 | Ats Holdings Llc | Simplified spine testing device |
| JP6182668B2 (ja) * | 2013-09-26 | 2017-08-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 画像化ツールとしてのイミダゾ［１，２−ａ］ピリジン−７−アミン |
| AR097683A1 (es) * | 2013-09-26 | 2016-04-06 | Lilly Co Eli | Compuestos y uso para la preparación de agentes de formación de imagen tau y formulaciones para la formación de imagen tau |
| SG11201603131RA (en) * | 2013-10-22 | 2016-05-30 | Clino Ltd | Tau imaging probe |
| AU2015247817C1 (en) * | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| HUE054149T2 (hu) * | 2015-06-04 | 2021-08-30 | Arvinas Operations Inc | Proteolízis imid-alapú modulátorai és ezekkel kapcsolatos felhasználási eljárások |
| CA2988436A1 (en) * | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
| WO2017024318A1 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| EP3337476A4 (en) * | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| IL290809B2 (en) * | 2016-11-01 | 2024-01-01 | Arvinas Operations Inc | Tau-protein targeting protacs and associated methods of use |
| CN106543185B (zh) * | 2016-11-10 | 2017-12-15 | 吉林大学 | 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
| EP3652329B1 (en) * | 2017-07-12 | 2023-10-04 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
-
2018
- 2018-07-12 EP EP18831849.7A patent/EP3652329B1/en active Active
- 2018-07-12 US US16/630,294 patent/US20210154184A1/en not_active Abandoned
- 2018-07-12 CA CA3069181A patent/CA3069181A1/en active Pending
- 2018-07-12 JP JP2020501505A patent/JP7260521B2/ja active Active
- 2018-07-12 AU AU2018300982A patent/AU2018300982B2/en active Active
- 2018-07-12 WO PCT/US2018/041787 patent/WO2019014429A1/en not_active Ceased
- 2018-07-12 ES ES18831849T patent/ES2965049T3/es active Active
- 2018-07-12 EP EP23195169.0A patent/EP4310496A3/en active Pending
-
2023
- 2023-04-06 JP JP2023062212A patent/JP2023106366A/ja not_active Withdrawn
- 2023-05-23 US US18/200,950 patent/US20240091213A1/en active Pending
-
2024
- 2024-12-02 JP JP2024209477A patent/JP2025060612A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020527559A5 (https=) | ||
| JP2023106366A5 (https=) | ||
| JP2019537599A5 (https=) | ||
| ES2689029T3 (es) | Hidratos de cloruro de metiltioninio cristalinos - Parte 2 | |
| RU2009104764A (ru) | Производные пурина, как антангонисты a2a | |
| JP2016510038A5 (https=) | ||
| JP2008510828A5 (https=) | ||
| JP2016509047A5 (https=) | ||
| JP2012513409A5 (https=) | ||
| JP2012513410A5 (https=) | ||
| JP2010501478A5 (https=) | ||
| JP2015520769A5 (https=) | ||
| JP2012517428A5 (https=) | ||
| JP2018516238A5 (https=) | ||
| JP2017531624A5 (https=) | ||
| JP2016506962A5 (https=) | ||
| AR042531A1 (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal | |
| CY1118390T1 (el) | Θεραπευτικος παραγων για τη φλεγμονωδη νοσο του εντερου | |
| JP2015526453A5 (https=) | ||
| JP2015532295A5 (https=) | ||
| JP2008528447A5 (https=) | ||
| JP2010524947A5 (https=) | ||
| JP2010530403A5 (https=) | ||
| JP2011506566A5 (https=) | ||
| WO2005042530A1 (en) | Rsv polymerase inhibitors |